ZHU Zheng-fei, TAN Pei-xin. GEMSTONE-301: Sugemalimab as a Consolidation Treatment After Concurrent or Sequential Chemoradiotherapy Improves the Survival of Patients With Unresectable StageⅢ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 4-7. DOI: 10.12019/j.issn.1671-5144.2022.01.002
|
Citation:
|
ZHU Zheng-fei, TAN Pei-xin. GEMSTONE-301: Sugemalimab as a Consolidation Treatment After Concurrent or Sequential Chemoradiotherapy Improves the Survival of Patients With Unresectable StageⅢ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 4-7. DOI: 10.12019/j.issn.1671-5144.2022.01.002
|
ZHU Zheng-fei, TAN Pei-xin. GEMSTONE-301: Sugemalimab as a Consolidation Treatment After Concurrent or Sequential Chemoradiotherapy Improves the Survival of Patients With Unresectable StageⅢ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 4-7. DOI: 10.12019/j.issn.1671-5144.2022.01.002
|
Citation:
|
ZHU Zheng-fei, TAN Pei-xin. GEMSTONE-301: Sugemalimab as a Consolidation Treatment After Concurrent or Sequential Chemoradiotherapy Improves the Survival of Patients With Unresectable StageⅢ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 4-7. DOI: 10.12019/j.issn.1671-5144.2022.01.002
|
DownLoad: